491 related articles for article (PubMed ID: 10323558)
1. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
[TBL] [Abstract][Full Text] [Related]
2. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
3. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
[TBL] [Abstract][Full Text] [Related]
4. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
[TBL] [Abstract][Full Text] [Related]
5. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
Guillon G; Pena A; Murat B; Derick S; Trueba M; Ventura MA; Szeto HH; Wo N; Stoev S; Cheng LL; Manning M
J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
[TBL] [Abstract][Full Text] [Related]
6. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of potent, highly selective vasopressin hypotensive agonists.
Stoev S; Cheng LL; Manning M; Wo NC; Szeto HH
J Pept Sci; 2006 Sep; 12(9):592-604. PubMed ID: 16625682
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 1999 Nov; 5(11):472-90. PubMed ID: 10587312
[TBL] [Abstract][Full Text] [Related]
9. Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
Manning M; Cheng LL; Klis WA; Balaspiri L; Olma A; Sawyer WH; Wo NC; Chan WY
J Med Chem; 1995 May; 38(10):1762-9. PubMed ID: 7752199
[TBL] [Abstract][Full Text] [Related]
10. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
[TBL] [Abstract][Full Text] [Related]
12. Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4.
Manning M; Nawrocka E; Misicka A; Olma A; Klis WA; Seto J; Sawyer WH
J Med Chem; 1984 Apr; 27(4):423-9. PubMed ID: 6708045
[TBL] [Abstract][Full Text] [Related]
13. Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids.
Manning M; Przybylski J; Grzonka Z; Nawrocka E; Lammek B; Misicka A; Cheng LL; Chan WY; Wo NC; Sawyer WH
J Med Chem; 1992 Oct; 35(21):3895-904. PubMed ID: 1433200
[TBL] [Abstract][Full Text] [Related]
14. Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4.
Manning M; Olma A; Klis WA; Seto J; Sawyer WH
J Med Chem; 1983 Nov; 26(11):1607-13. PubMed ID: 6631916
[TBL] [Abstract][Full Text] [Related]
15. Influence of enantiomers of 1-naphthylalanine in position 2 of VAVP and dVAVP on their pharmacological properties.
Derdowska I; Prahl A; Kowalczyk W; Janecki M; Melhem S; Trzeciak HI; Lammek B
Eur J Med Chem; 2005 Jan; 40(1):63-8. PubMed ID: 15642410
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
[TBL] [Abstract][Full Text] [Related]
17. Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin.
Kowalczyk W; Prahl A; Derdowska I; Dawidowska O; Slaninová J; Lammek B
J Med Chem; 2004 Nov; 47(24):6020-4. PubMed ID: 15537356
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.
Manning M; Miteva K; Pancheva S; Stoev S; Wo NC; Chan WY
Int J Pept Protein Res; 1995; 46(3-4):244-52. PubMed ID: 8537178
[TBL] [Abstract][Full Text] [Related]
19. Biological activities of some new arginine vasopressin analogues containing unusual amino acids.
Varga C; Somlai C; Baláspiri L; László FA
Acta Physiol Hung; 1993; 81(2):183-92. PubMed ID: 8197874
[TBL] [Abstract][Full Text] [Related]
20. Analogues of arginine vasopressin modified in position 2 and 3 with conformationally constrained dipeptide fragments.
Łempicka E; Derdowska I; Kowalczyk W; Dawidowska O; Prahl A; Janecki M; Jasiński T; Trzeciak HI; Lammek B
J Pept Sci; 2005 Feb; 11(2):91-6. PubMed ID: 15635636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
